EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RASAL2 activates RAC1 to promote triple-negative breast cancer progression



RASAL2 activates RAC1 to promote triple-negative breast cancer progression



Journal of Clinical Investigation 124(12): 5291-5304



Patients with triple-negative breast cancer (TNBC) have a high incidence of early relapse and metastasis; however, the molecular basis for recurrence in these individuals remains poorly understood. Here, we demonstrate that RASAL2, which encodes a RAS-GTPase-activating protein (RAS-GAP), is a functional target of anti-invasive microRNA-203 and is overexpressed in a subset of triple-negative or estrogen receptor-negative (ER-negative) breast tumors. As opposed to luminal B ER-positive breast cancers, in which RASAL2 has been shown to act as a RAS-GAP tumor suppressor, we found that RASAL2 is oncogenic in TNBC and drives mesenchymal invasion and metastasis. Moreover, high RASAL2 expression was predictive of poor disease outcomes in patients with TNBC. RASAL2 acted independently of its RAS-GAP catalytic activity in TNBC; however, RASAL2 promoted small GTPase RAC1 signaling, which promotes mesenchymal invasion, through binding and antagonizing the RAC1-GAP protein ARHGAP24. Together, these results indicate that activation of a RASAL2/ARHGAP24/RAC1 module contributes to TNBC tumorigenesis and identify a context-dependent role of RASAL2 in breast cancer.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333445

Download citation: RISBibTeXText

PMID: 25384218

DOI: 10.1172/JCI76711



Related references

miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer. Oncology Reports 36(1): 65-71, 2016

Tryptophan hydroxylase 1 and 5-HT7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling. Molecular Cancer 15(1): 75-75, 2017

The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression. Molecular Cancer 18(1): 4-4, 2019

Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis. Breast Care 10(6): 413-416, 2016

Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway. Cancer Letters: -, 2018

Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. Genes & Development 31(16): 1641-1654, 2017

Low dose of kaempferol suppresses the migration and invasion of triple-negative breast cancer cells by downregulating the activities of RhoA and Rac1. Oncotargets and Therapy 10: 4809-4819, 2017

Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer. Plos One 11(10): E0165005-E0165005, 2016

Downregulation of Dock1 and Elmo1 suppresses the migration and invasion of triple-negative breast cancer epithelial cells through the RhoA/Rac1 pathway. Oncology Letters 16(3): 3481-3488, 2018

miR-221/222 activate the Wnt/β-catenin signaling to promote triple negative breast cancer. Journal of Molecular Cell Biology: -, 2018

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells. Oncotarget 8(13): 21626-21638, 2017

TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer. Cancer Research: -, 2018

MicroRNA-182 targets FOXF2 to promote the development of triple-negative breast cancer. Neoplasma 64(2): 209-215, 2017

The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data. Breast Cancer Research 16(6): 490-490, 2015

Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer. Tumour Biology 35(10): 9751-9757, 2015